Zantac (Ranitidine) Leads
Connect with individuals who developed bladder, stomach, liver, or other cancers after long-term use of Zantac or generic ranitidine contaminated with NDMA.
Zantac Ranitidine Litigation
Zantac (ranitidine), one of the world's most widely used heartburn and acid reflux medications, was found to contain N-Nitrosodimethylamine (NDMA), a probable human carcinogen. The FDA requested manufacturers withdraw all ranitidine products from the market in 2020 after testing confirmed NDMA levels increased over time and with higher storage temperatures. Lawsuits allege manufacturers including Sanofi, Boehringer Ingelheim, and GlaxoSmithKline knew about the NDMA contamination risk and failed to warn consumers.
Associated Conditions
- Bladder cancer
- Stomach cancer (gastric cancer)
- Liver cancer (hepatocellular carcinoma)
- Esophageal cancer
- Pancreatic cancer
- Kidney cancer
- Colorectal cancer
Claimant Eligibility
- Used Zantac or generic ranitidine regularly for six months or longer
- Diagnosed with cancer potentially linked to NDMA exposure
- Purchase records, prescription history, or pharmacy records for ranitidine
- Cancer diagnosis occurred during or after regular Zantac use
- No other primary known cause of the cancer diagnosis
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Running a Zantac (Ranitidine) mass tort marketing campaign
Common questions from law firms about Zantac (Ranitidine) lead generation and campaign management.
- What does a Zantac (Ranitidine) mass tort marketing campaign include?
- A Zantac (Ranitidine) mass tort marketing campaign from Mass Tort Marketing Agency covers channel strategy across Meta, Google/PPC, OTT, and mass tort SEO; compliant ad creative; TCPA-verified intake; claimant qualification against your Zantac (Ranitidine) case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- Are Zantac (Ranitidine) leads exclusive to my firm?
- Yes. Every Zantac (Ranitidine) lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Zantac (Ranitidine) claimants qualified before delivery?
- Each Zantac (Ranitidine) claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a TrustedForm or Jornaya consent token captured under the FCC one-to-one consent standard before the lead reaches your intake team.
- How is a Zantac (Ranitidine) campaign priced?
- Campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. You can scale volume up or down by tort as your docket capacity changes.
See how every lead is qualified on our mass tort leads page, or compare providers in our top mass tort marketing firms guide.